ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2017
Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics.EJNMMI research · 2025Review
- Strategic Integration: A Cross-Disciplinary Review of the fNIRS-EEG Dual-Modality Imaging System for Delivering Multimodal Neuroimaging to Applications.Brain sciences · 2024Review
- Synthesis and preclinical evaluation of aScientific reports · 2024Article
- Detection of Shortwave-Infrared Cerenkov Luminescence from Medical Isotopes.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Synthesis andBioconjugate chemistry · 2022Article
- In situ lymphoma imaging in a spontaneous mouse model using the Cerenkov Luminescence of F-18 and Ga-67 isotopes.Scientific reports · 2021Article
- A review of recent and emerging approaches for the clinical application of Cerenkov luminescence imaging.Frontiers in physics · 2021Article
- Site-specific antibody fragment conjugates for targeted imaging.Methods in enzymology · 2020Article
- Removal of random-valued impulse noise from Cerenkov luminescence images.Medical & biological engineering & computing · 2020Article
- Design of Cerenkov Radiation-Assisted Photoactivation of TiOJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection.Journal of labelled compounds & radiopharmaceuticals · 2018Review
- Cerenkov luminescence imaging: physics principles and potential applications in biomedical sciences.EJNMMI physics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Antibodies, and engineered antibody fragments, labeled with radioisotopes are being developed as radiotracers for the detection and phenotyping of diseases such as cancer. The development of antibody-based radiotracers requires extensive characterization of their in vitro and in vivo properties, including their ability to target tumors in an antigen-selective manner. In this study, we investigated the use of Cerenkov luminescence imaging (CLI) as compared with PET as a modality for evaluating the in vivo behavior of antibody-based radiotracers.
methodsThe anti-prostate-specific membrane antigen (PSMA) huJ591 antibody (IgG; 150 kDa) and its minibody (Mb; 80 kDa) format were functionalized with the chelator 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA) and radiolabeled with the positron-emitting radionuclide
results
conclusionCLI provided a rapid and simple assessment of the targeting specificity and pharmacokinetics of the antibody-based PET radiotracers that correlated well with the behavior observed by standard PET imaging. Moreover, CLI provided clear discrimination between uptake kinetics of an intact IgG and its small-molecular-weight derivative Mb. These data support the use of CLI for the evaluation of radiotracer performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.